
Helene Cabanas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2506941/publications.pdf Version: 2024-02-01



HELENE CABANAS

#	Article	IF	CITATIONS
1	A systematic review of neurological impairments in myalgic encephalomyelitis/ chronic fatigue syndrome using neuroimaging techniques. PLoS ONE, 2020, 15, e0232475.	2.5	43
2	A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome. Systematic Reviews, 2019, 8, 279.	5.3	42
3	A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease. Journal of Translational Medicine, 2020, 18, 290.	4.4	36
4	A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis. Systematic Reviews, 2018, 7, 241.	5.3	34
5	Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. Molecular Medicine, 2018, 24, 44.	4.4	29
6	A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID). BMC Neurology, 2019, 19, 207.	1.8	29
7	Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. Frontiers in Immunology, 2019, 10, 2545.	4.8	22
8	Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients. Molecular Medicine, 2019, 25, 14.	4.4	20
9	Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment. Frontiers in Immunology, 2021, 12, 687806.	4.8	17
10	Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients. Journal of Translational Medicine, 2019, 17, 401.	4.4	13
11	Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia. Oncotarget, 2018, 9, 26309-26327.	1.8	13
12	A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Translational Medicine, 2021, 19, 81.	4.4	9
13	The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients. Journal of Translational Medicine, 2021, 19, 306.	4.4	9
14	Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. Journal of Translational Medicine, 2022, 20, 94.	4.4	8
15	Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Healthcare (Switzerland), 2021, 9, 568.	2.0	5
16	Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation. BMC Pharmacology & Toxicology, 2018, 19, 12.	2.4	3
17	Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review. International Journal of Environmental Research and Public Health, 2021, 18, 10708.	2.6	3
18	A preliminary investigation of nutritional intake and supplement use in Australians with myalgic encephalomyelitis/chronic fatigue syndrome and the implications on health-related quality of life. Food and Nutrition Research, 2021, 65, .	2.6	2

HELENE CABANAS

#	Article	IF	CITATIONS
19	Characterization of IL-2 Stimulation and TRPM7 Pharmacomodulation in NK Cell Cytotoxicity and Channel Co-Localization with PIP2 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. International Journal of Environmental Research and Public Health, 2021, 18, 11879.	2.6	2
20	Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry. BMC Immunology, 2019, 20, 14.	2.2	1
21	109â€Investigation of natural killer cell function and phenotypes in stable and active multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A43.2-A43.	1.9	0
22	Title is missing!. , 2020, 15, e0232475.		0
23	Title is missing!. , 2020, 15, e0232475.		0
24	Title is missing!. , 2020, 15, e0232475.		0
25	Title is missing!. , 2020, 15, e0232475.		0
26	Title is missing!. , 2020, 15, e0232475.		0
27	Title is missing!. , 2020, 15, e0232475.		0